Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clémentine Sarkozy1, Gilles Salles2

  • 1Inserm U1052 CNRS 5286, centre de recherche en cancérologie de Lyon (CRCL), équipe « clinical and experimental models of lymphomagenesis », 69600 Lyon, France; Université de Lyon, université Claude-Bernard Lyon 1, faculté de médecine et de maïeutique Lyon-Sud-Charles-Mérieux, 69600 Lyon, France.

Presse Medicale (Paris, France : 1983)
|August 27, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026
Same author

Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach.

Critical reviews in oncology/hematology·2026
Same author

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Cancer discovery·2026
Same author

Large B-cell lymphoma: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990)·2025
Same author

All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?

Hematology. American Society of Hematology. Education Program·2025
Same author

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Blood advances·2025

Advances in treating non-follicular small cell lymphomas have improved patient outcomes. New therapies offer better prognoses for MALT, mantle cell, and marginal zone lymphomas, leading to longer, often treatment-free, survivals.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Non-follicular small cell lymphomas encompass several distinct entities.
  • Recent decades have seen significant refinement in their clinical and pathological understanding.

Purpose of the Study:

  • To review and summarize recent advancements in the diagnosis and treatment of non-follicular small cell lymphomas.
  • To highlight the evolving therapeutic landscape and improved prognoses for these conditions.

Main Methods:

  • Literature review of clinical and pathological studies published in the last 20 years.
  • Analysis of treatment strategies for specific non-follicular small cell lymphoma subtypes, including MALT lymphoma, mantle cell lymphoma, and splenic nodal marginal zone lymphoma.

Main Results:

Related Experiment Videos

  • MALT lymphoma treatment varies from infectious agent eradication to anti-CD20 antibodies and cytotoxic agents.
  • Mantle cell lymphoma management has advanced with chemotherapy, anti-CD20 antibodies, autologous stem cell transplant, and targeted therapies like ibrutinib.
  • Splenic nodal marginal zone lymphomas benefit from immunochemotherapy, among other options.

Conclusions:

  • Despite being considered incurable, the prognosis for non-follicular small cell lymphomas has markedly improved.
  • Many patients now experience significantly longer survival, often with extended treatment-free intervals, due to therapeutic progress.